A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

August 31, 2014

Conditions

Diabetes Mellitus Type 1

Interventions

DRUG

BioChaperone insulin lispro

Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)

DRUG

Humalog®

Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)

Trial Locations (1)

Neuss